Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

Phase 1 Completed 11 enrolled TransThera Sciences (Nanjing), Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study of the safety, tolerability, pharmacokinetics profile, and preliminary efficacy of TT-00434 in patients with advanced solid tumors.

Timeline

Start: 2021-07-12
Primary completion: 2023-10-18
Completion: 2023-10-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TT-00434	Unknown	—	—

Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications